Literature DB >> 25212426

N-Acetylcysteine for thrombotic thrombocytopenic purpura: is a von Willebrand factor-inhibitory dose feasible in vivo?

Jake Shortt1, Stephen S Opat, Erica M Wood.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25212426     DOI： 10.1111/trf.12787

Source DB:  PubMed          Journal:  Transfusion        ISSN： 0041-1132            Impact factor:   3.157


× No keyword cloud information.
  4 in total

Review 1.  How I treat refractory thrombotic thrombocytopenic purpura.

Authors:  Farzana A Sayani; Charles S Abrams
Journal:  Blood       Date:  2015-03-17       Impact factor: 22.113

Review 2.  The role of von Willebrand factor in thrombotic microangiopathy.

Authors:  Damien G Noone; Magdalena Riedl; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2017-07-26       Impact factor: 3.714

3.  The role of N-acetylcysteine in the treatment of thrombotic thrombocytopenic purpura.

Authors:  Amihai Rottenstreich; Sarit Hochberg-Klein; Deborah Rund; Yosef Kalish
Journal:  J Thromb Thrombolysis       Date:  2016-05       Impact factor: 2.300

4.  The antioxidant N-acetylcysteine promotes immune response and inhibits epithelial-mesenchymal transition to alleviate pulmonary fibrosis in chronic obstructive pulmonary disease by suppressing the VWF/p38 MAPK axis.

Authors:  Lanlan Zhu; Fei Xu; Xiuhua Kang; Jing Zhou; Qinqin Yao; Yang Lin; Wei Zhang
Journal:  Mol Med       Date:  2021-09-03       Impact factor: 6.354
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.